Ricoh USA Sells Healthcare 3D Printing Unit, Rebranded as Myrava
Ricoh USA has sold its 3D for Healthcare division, a spin-off established last year, to former VP and General Manager Gary Turner, who has rebranded the company as Myrava.
Ricoh USA has sold its specialized healthcare 3D printing division, formerly known as Ricoh 3D for Healthcare, to Gary Turner, who previously served as the VP and GM of Additive Manufacturing at Ricoh USA. The newly independent entity has been rebranded as Myrava.
Under Turner's guidance, Ricoh 3D for Healthcare achieved numerous FDA clearances for patient-specific anatomical models. He was also instrumental in establishing an Additive Manufacturing Center of Excellence in partnership with North Carolina State University in 2024, strengthening the company's presence in a key medical innovation hub.
The division's success was built on strong relationships with healthcare providers, enabling point-of-care service delivery. Myrava’s website indicates a continued focus on this aspect of the business.
While the additive manufacturing industry's focus has expanded, the medical sector remains a highly valuable market segment. The ongoing demand for personalized medical solutions is expected to drive continued growth in this area, with the United States maintaining its leading position in the global medical device market.
Bob Lamendola, Chief Digital Services and Delivery Officer at Ricoh USA, stated that while healthcare is a key growth area for Ricoh, patient-specific medical devices require specialized capabilities beyond their broader business priorities. This sale allows the business to scale under dedicated ownership while Ricoh concentrates on its core offerings to healthcare providers, aiming to reduce costs, facilitate compliance, improve efficiency, and enhance patient and clinician experiences.
Gary Turner, now CEO of Myrava, Inc., commented that Ricoh's earlier step in making Ricoh 3D for Healthcare a standalone entity created the necessary focus for this specialized market. As an independent company, Myrava will benefit from dedicated investment and leadership focused on advancing personalized, FDA-cleared medical devices and point-of-care manufacturing.
This divestiture highlights the trend of specialized additive manufacturing divisions becoming independent entities to better serve niche markets like healthcare. The focus on FDA-cleared, patient-specific devices is crucial for medical applications, requiring dedicated investment and expertise. Myrava's continued emphasis on point-of-care manufacturing signifies a strategic move towards decentralized medical production, a key development in the broader AM landscape.
Edited by the news editor with AI from the original report — please refer to the original source.